• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于脓毒症诊断和治疗的纳米工具。

Nanotools for Sepsis Diagnosis and Treatment.

作者信息

Papafilippou Lana, Claxton Andrew, Dark Paul, Kostarelos Kostas, Hadjidemetriou Marilena

机构信息

Nanomedicine Lab, Faculty of Biology, Medicine and Health, AV Hill Building, The University of Manchester, Manchester, M13 9PT, UK.

Department of Critical Care, Salford Royal Foundation Trust, Stott Lane, Salford, M6 8HD, UK.

出版信息

Adv Healthc Mater. 2021 Jan;10(1):e2001378. doi: 10.1002/adhm.202001378. Epub 2020 Nov 25.

DOI:10.1002/adhm.202001378
PMID:33236524
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11469323/
Abstract

Sepsis is one of the leading causes of death worldwide with high mortality rates and a pathological complexity hindering early and accurate diagnosis. Today, laboratory culture tests are the epitome of pathogen recognition in sepsis. However, their consistency remains an issue of controversy with false negative results often observed. Clinically used blood markers, C reactive protein (CRP) and procalcitonin (PCT) are indicators of an acute-phase response and thus lack specificity, offering limited diagnostic efficacy. In addition to poor diagnosis, inefficient drug delivery and the increasing prevalence of antibiotic-resistant microorganisms constitute significant barriers in antibiotic stewardship and impede effective therapy. These challenges have prompted the exploration for alternative strategies that pursue accurate diagnosis and effective treatment. Nanomaterials are examined for both diagnostic and therapeutic purposes in sepsis. The nanoparticle (NP)-enabled capture of sepsis causative agents and/or sepsis biomarkers in biofluids can revolutionize sepsis diagnosis. From the therapeutic point of view, currently existing nanoscale drug delivery systems have proven to be excellent allies in targeted therapy, while many other nanotherapeutic applications are envisioned. Herein, the most relevant applications of nanomedicine for the diagnosis, prognosis, and treatment of sepsis is reviewed, providing a critical assessment of their potentiality for clinical translation.

摘要

脓毒症是全球主要的死亡原因之一,死亡率高,且病理复杂性阻碍了早期准确诊断。如今,实验室培养检测是脓毒症病原体识别的典范。然而,其一致性仍是一个有争议的问题,经常出现假阴性结果。临床使用的血液标志物,如C反应蛋白(CRP)和降钙素原(PCT)是急性期反应的指标,因此缺乏特异性,诊断效能有限。除了诊断不佳外,药物递送效率低下以及抗生素耐药微生物的日益流行,在抗生素管理方面构成了重大障碍,阻碍了有效治疗。这些挑战促使人们探索追求准确诊断和有效治疗的替代策略。纳米材料在脓毒症的诊断和治疗方面都得到了研究。纳米颗粒(NP)在生物流体中捕获脓毒症病原体和/或脓毒症生物标志物可彻底改变脓毒症诊断。从治疗角度来看,目前现有的纳米级药物递送系统已被证明是靶向治疗的优秀盟友,同时还设想了许多其他纳米治疗应用。本文综述了纳米医学在脓毒症诊断、预后和治疗方面的最相关应用,并对其临床转化潜力进行了批判性评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/92f21cd21426/ADHM-10-2001378-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/60c16545a0a1/ADHM-10-2001378-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/7383c562772d/ADHM-10-2001378-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/0cfb3fd1a6d7/ADHM-10-2001378-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/acac94bdafda/ADHM-10-2001378-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/d02433a4b20f/ADHM-10-2001378-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/3cce1a1bc274/ADHM-10-2001378-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/922b3695c810/ADHM-10-2001378-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/a7e548164dee/ADHM-10-2001378-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/92f21cd21426/ADHM-10-2001378-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/60c16545a0a1/ADHM-10-2001378-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/7383c562772d/ADHM-10-2001378-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/0cfb3fd1a6d7/ADHM-10-2001378-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/acac94bdafda/ADHM-10-2001378-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/d02433a4b20f/ADHM-10-2001378-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/3cce1a1bc274/ADHM-10-2001378-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/922b3695c810/ADHM-10-2001378-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/a7e548164dee/ADHM-10-2001378-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50f/11469323/92f21cd21426/ADHM-10-2001378-g007.jpg

相似文献

1
Nanotools for Sepsis Diagnosis and Treatment.用于脓毒症诊断和治疗的纳米工具。
Adv Healthc Mater. 2021 Jan;10(1):e2001378. doi: 10.1002/adhm.202001378. Epub 2020 Nov 25.
2
The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills?降钙素原作为脓毒症管理中生物标志物的功效:屠龙之举还是徒劳无功?
Surg Infect (Larchmt). 2013 Dec;14(6):489-511. doi: 10.1089/sur.2012.028. Epub 2013 Nov 25.
3
Clinical Utility of Procalcitonin and C-Reactive Protein in the Management of Neonatal Sepsis in a Resource-Limited Nigerian Hospital.降钙素原和 C 反应蛋白在资源有限的尼日利亚医院新生儿脓毒症管理中的临床应用。
Niger J Clin Pract. 2023 Dec 1;26(12):1895-1901. doi: 10.4103/njcp.njcp_397_23. Epub 2023 Dec 29.
4
Role of procalcitonin, C-reactive protein, interleukin-6, interleukin-8 and tumor necrosis factor-alpha in the diagnosis of neonatal sepsis.降钙素原、C反应蛋白、白细胞介素-6、白细胞介素-8及肿瘤坏死因子-α在新生儿败血症诊断中的作用
Turk J Pediatr. 2007 Jan-Mar;49(1):7-20.
5
Diagnostic and prognostic biomarkers of sepsis in critical care.重症监护中脓毒症的诊断和预后生物标志物。
J Antimicrob Chemother. 2011 Apr;66 Suppl 2:ii33-40. doi: 10.1093/jac/dkq523.
6
Procalcitonin: potential role in diagnosis and management of sepsis.降钙素原:在脓毒症诊断和管理中的潜在作用。
Adv Clin Chem. 2015;68:71-86. doi: 10.1016/bs.acc.2014.11.005. Epub 2015 Jan 7.
7
A randomized trial to compare procalcitonin and C-reactive protein in assessing severity of sepsis and in guiding antibacterial therapy in Egyptian critically ill patients.一项比较降钙素原和 C 反应蛋白在评估埃及危重症患者脓毒症严重程度和指导抗菌治疗中的随机试验。
Ir J Med Sci. 2021 Nov;190(4):1487-1495. doi: 10.1007/s11845-020-02494-y. Epub 2021 Jan 14.
8
Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial.降钙素原指导决策在疑似新生儿早发性败血症中的应用:前瞻性随机干预试验。
Neonatology. 2010;97(2):165-74. doi: 10.1159/000241296. Epub 2009 Sep 24.
9
C-Reactive Protein, Procalcitonin, and White Blood Count to Rule Out Neonatal Early-onset Sepsis Within 36 Hours: A Secondary Analysis of the Neonatal Procalcitonin Intervention Study.C 反应蛋白、降钙素原和白细胞计数用于 36 小时内排除新生儿早发性败血症:新生儿降钙素原干预研究的二次分析。
Clin Infect Dis. 2021 Jul 15;73(2):e383-e390. doi: 10.1093/cid/ciaa876.
10
Reliability of serum procalcitonin concentrations for the diagnosis of sepsis in neonates.血清降钙素原浓度在新生儿脓毒症诊断中的可靠性
Egypt J Immunol. 2008;15(1):75-84.

引用本文的文献

1
Electrochemical Aptamer-Based Biosensors for Sepsis Diagnosis: Recent Advances, Challenges, and Future Perspectives (2020-2025).用于脓毒症诊断的基于适配体的电化学生物传感器:最新进展、挑战及未来展望(2020 - 2025年)
Biosensors (Basel). 2025 Jun 20;15(7):402. doi: 10.3390/bios15070402.
2
Nanocarrier-Based Targeting of Pattern Recognition Receptors as an Innovative Strategy for Enhancing Sepsis Therapy.基于纳米载体靶向模式识别受体作为增强脓毒症治疗的创新策略
Adv Healthc Mater. 2025 Sep;14(23):e2501146. doi: 10.1002/adhm.202501146. Epub 2025 Jul 2.
3
Advancements, Challenges, and Future Prospects of Nanotechnology in Sepsis Therapy.

本文引用的文献

1
Nanoparticle-based mobile biosensors for the rapid detection of sepsis biomarkers in whole blood.用于快速检测全血中脓毒症生物标志物的基于纳米颗粒的移动生物传感器。
Nanoscale Adv. 2020 Jan 22;2(3):1253-1260. doi: 10.1039/d0na00026d. eCollection 2020 Mar 17.
2
Graphene-Based Materials for the Fast Removal of Cytokines from Blood Plasma.用于从血浆中快速去除细胞因子的石墨烯基材料
ACS Appl Bio Mater. 2018 Aug 20;1(2):436-443. doi: 10.1021/acsabm.8b00151. Epub 2018 Aug 1.
3
Duplex Shiny app quantification of the sepsis biomarkers C-reactive protein and interleukin-6 in a fast quantum dot labeled lateral flow assay.
纳米技术在脓毒症治疗中的进展、挑战与未来前景
Int J Nanomedicine. 2025 Jun 16;20:7685-7714. doi: 10.2147/IJN.S488026. eCollection 2025.
4
Antibacterial gold nanoclusters combined with meropenem for the treatment of sepsis by alleviating the cytokine storm.抗菌金纳米团簇联合美罗培南通过减轻细胞因子风暴治疗脓毒症。
Nanoscale Adv. 2025 Jun 4. doi: 10.1039/d5na00234f.
5
Prognostic value of HSP27 in 28-day mortality in septic ICU patients: a retrospective cohort study.热休克蛋白27对脓毒症重症监护病房患者28天死亡率的预后价值:一项回顾性队列研究
Front Med (Lausanne). 2025 Jan 9;11:1513788. doi: 10.3389/fmed.2024.1513788. eCollection 2024.
6
Small molecule modulation of protein corona for deep plasma proteome profiling.小分子调控蛋白冠用于深度血浆蛋白质组分析。
Nat Commun. 2024 Nov 7;15(1):9638. doi: 10.1038/s41467-024-53966-z.
7
Encapsulation of the PHMB with nanoliposome and attachment to wound dressing for long-term antibacterial activity and biocompatibility.采用纳米脂质体包裹 PHMB,并将其附着于伤口敷料上,以实现长效抗菌活性和生物相容性。
World J Microbiol Biotechnol. 2024 Oct 23;40(11):361. doi: 10.1007/s11274-024-04170-0.
8
The Preventive and Therapeutic Effects of Acute and Severe Inflammatory Disorders with Heparin and Heparinoid.肝素和类肝素在急性和重度炎症紊乱中的预防和治疗作用。
Biomolecules. 2024 Aug 28;14(9):1078. doi: 10.3390/biom14091078.
9
The value of IL-6, PCT, qSOFA, NEWS, and SIRS to predict septic shock after Percutaneous nephrolithotomy.白细胞介素-6、降钙素原、快速序贯器官衰竭评估、新苏格兰临床评分和全身炎症反应综合征对经皮肾镜碎石术后脓毒性休克的预测价值。
BMC Urol. 2024 Jun 7;24(1):116. doi: 10.1186/s12894-024-01502-y.
10
Progress in Procalcitonin Detection Based on Immunoassay.基于免疫分析的降钙素原检测进展
Research (Wash D C). 2024 Apr 16;7:0345. doi: 10.34133/research.0345. eCollection 2024.
基于快速量子点标记侧向流法的双荧光 shiny 应用程序对脓毒症生物标志物 C 反应蛋白和白细胞介素 6 的定量检测。
J Nanobiotechnology. 2020 Sep 10;18(1):130. doi: 10.1186/s12951-020-00688-1.
4
The challenge of recognising sepsis: Future nanotechnology solutions.识别脓毒症的挑战:未来的纳米技术解决方案。
J Intensive Care Soc. 2020 Aug;21(3):241-246. doi: 10.1177/1751143719896554. Epub 2019 Dec 18.
5
Treatment of severe sepsis with nanoparticulate cell-free DNA scavengers.纳米颗粒无细胞 DNA 清除剂治疗严重脓毒症。
Sci Adv. 2020 May 29;6(22):eaay7148. doi: 10.1126/sciadv.aay7148. eCollection 2020 May.
6
Personalized protein coronas: a "key" factor at the nanobiointerface.个性化蛋白质冠层:纳米生物界面的“关键”因素。
Biomater Sci. 2014 Sep 29;2(9):1210-1221. doi: 10.1039/c4bm00131a. Epub 2014 May 30.
7
Nano-Based Drug Delivery or Targeting to Eradicate Bacteria for Infection Mitigation: A Review of Recent Advances.基于纳米的药物递送或靶向以根除细菌减轻感染:近期进展综述
Front Chem. 2020 Apr 24;8:286. doi: 10.3389/fchem.2020.00286. eCollection 2020.
8
Protein corona fingerprinting to differentiate sepsis from non-infectious systemic inflammation.通过蛋白质冠指纹图谱区分脓毒症与非感染性全身炎症。
Nanoscale. 2020 May 14;12(18):10240-10253. doi: 10.1039/d0nr02788j.
9
Experience with hemoadsorption (CytoSorb) in the management of septic shock patients.血液吸附(CytoSorb)在脓毒性休克患者治疗中的应用经验。
World J Crit Care Med. 2020 Jan 31;9(1):1-12. doi: 10.5492/wjccm.v9.i1.1.
10
Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis.维生素脂质纳米粒使巨噬细胞过继转移治疗多重耐药菌脓毒症成为可能。
Nat Nanotechnol. 2020 Jan;15(1):41-46. doi: 10.1038/s41565-019-0600-1. Epub 2020 Jan 6.